Encouraging clinical results across various metabolic, hematological and ophthalmic disorders have inspired research groups across the world to focus their efforts on the development of novel gene editing therapies. In fact, the gene therapy pipeline has evolved significantly over the past few years, with three products being approved in 2019 alone; namely Beperminogene perplasmid (AnGes), ZOLGENSMA® (AveXis) and ZYNTEGLO™ (bluebird bio). Further, there are multiple pipeline candidates in mid to late-stage (phase II and above) trials that are anticipated to enter the market over the next 5-10 years.
To order this 670+ page report, which features 190+ figures and 340+ tables, please visit this – https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html
The USD 11.6 billion (by 2030) financial opportunity within the gene therapy market has been analyzed across the following segments:
Key therapeutic areas
Autoimmune disorders
Cardiovascular diseases
Genetic disorders
Hematological disorders
Metabolic disorders
Ophthalmic disorders
Oncological disorders
Others
- Type of vector
- Adeno associated virus
- Adenovirus
- Herpes simplex virus type 1
- Lentivirus
- Plasmid DNA
- Retrovirus
- Vaccinia Virus
Type of therapy
- Ex vivo
- In vivo
Type of gene modification
- Gene augmentation
- Immunotherapy
- Oncolytic therapy
- Others
Route of administration
- Intraarticular
- Intracerebellar
- Intramuscular
- Intradermal
- Intravenous
- Intravitreal
- Intravesical
- Subretinal
- Others
Key geographical regions
North America
Europe
Asia-Pacific
The Gene Therapy Market (3rd Edition), 2019-2030 report features the following companies, which we identified to be key players in this domain:
- Advantagene
- Advaxis
- BioMarin
- bluebird bio
- FKD Therapies
- Freeline Therapeutics
- GenSight Biologics
- Gradalis
- Inovio Pharmaceuticals
- Marsala Biotech
- Orchard Therapeutics
- Pfizer
- Sarepta Therapeutics
- Spark Therapeutics
- Tocagen
- Transgene
- uniQure Biopharma
- VBL Therapeutics
- ViroMed
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. Gene Delivery Vectors
5. Regulatory Landscape and Reimbursement Scenario
6. Competitive Landscape
7. Marketed Gene Therapies
8. Key Commercialization Strategies
9. Late Stage (Phase II/III and Above) Gene Therapies
10. Emerging Technologies
11. Promising Therapeutics Areas
12. Patent Analysis
13. Mergers and Acquisitions
14. Funding and Investment Analysis
15. Cost Price Analysis
16. Big Pharma Players: Analysis of Gene Therapy Related Initiatives
17. Market Forecast and Opportunity Analysis
18. Vector Manufacturing
19. Case Study: Gene Therapy Supply Chain
20. Conclusion
21. Interview Transcripts
22. Appendix 1: Tabulated Data
23. Appendix 2: List of Companies and Organizations
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/gene-therapy-market-3rd-edition-2019-2030/268.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
